THYROLAR-2
LOE ApproachingNDAORALTABLET
Approved
Nov 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THYROLAR-2 is an oral tablet approved in 1969 for thyroid hormone replacement therapy. The product mechanism of action and specific indications are not detailed in available data, but the brand name suggests a thyroid-related therapeutic application. It is a legacy small-molecule product with established clinical use.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30/100), commercial teams are likely focused on efficiency and managed decline rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
THYROLAR-2 offers limited career growth due to its mature, LOE-approaching status and zero linked job openings. Roles on this product focus on defending market share, managing generic transition, and operational efficiency rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on THYROLAR-2 at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.